Allergan Aesthetics Unveils Innovative Portfolio at the 5th China International Import Expo to Empower High-Quality Development of China's Aesthetic Medicine Industry
November 5, 2022, Shanghai— Allergan Aesthetics, a global leader in the medical aesthetics biopharmaceutical sector, and its parent company AbbVie jointly made their debut at the 5th China International Import Expo on the 5th. At the Medical Devices and Healthcare Section of the National Exhibition and Convention Center (Shanghai), Allergan Aesthetics will showcase innovative products in the fields of facial aesthetics and body contouring, including Botox®, Juvéderm®Series and CoolSculpting®Non-invasive Cryolipolysis Device, Functional Skincare Products Skinmedica®and the DiamondGlow skincare device, which is not yet marketed in China®...and other new products. Allergan Aesthetics will fully leverage the platform of the China International Import Expo (CIIE) to share insights on industry trends, deepen strategic collaborations with key partners, empower the high-quality development of China’s medical aesthetics industry, and help more individuals achieve confident beauty.
Jason Smith, Senior Vice President of Allergan Aesthetics and President of the International Divisionstated: “The China International Import Expo (CIIE) is a vital platform supporting global trade and economic cooperation, and we are delighted to participate. China is one of the most important markets for Allergan Aesthetics’ international business, and our active participation in the CIIE demonstrates our long-term commitment to the Chinese market and our partners in China.”
Wang Wei, President of Allergan Aesthetics Japan and Asia-Pacific Regionstated: “As a key subsidiary of AbbVie in China, Allergan Aesthetics has maintained strong growth momentum over the more than ten years since entering the Chinese market, and in recent years has rapidly become one of the important growth engines for its aesthetics business in the Asia-Pacific region and globally. Allergan Aesthetics will continue to deepen its efforts in product introduction, professional education, and industry ecosystem empowerment, continuously injecting momentum into the development of China’s medical aesthetics industry.”
丘汉华, General Manager of Allergan Aesthetics Chinastated: “As a leading upstream enterprise in the medical aesthetics industry, Allergan Aims to showcase the landscape of the sector and enhance public confidence through the China International Import Expo (CIIE). We will continue to expand development opportunities in core business areas such as facial aesthetics and body contouring, introduce one or two cutting-edge products annually, collaborate with partners to shape the industry’s future, and serve every consumer who seeks beauty with confidence.”
Over the past decade since entering China, Allergan Aesthetics has witnessed the country’s economy, society, and culture embrace openness, prosperity, and innovation at an unprecedented pace, as well as Chinese consumers’ growing aspiration for a better quality of life. The development of Allergan Aesthetics’ business in China is closely intertwined with the nation’s sustained economic growth and the steady rise in demand for medical aesthetics.
With the support of its global headquarters and the attention of local governments, Allergan Aesthetics has established its China regional headquarters in Shanghai. It has built two innovation centers in Shanghai and Chengdu, with professional medical aesthetics education as their primary function, and has entered into a strategic cooperation agreement with the Hainan Lecheng Pilot Zone for the pilot testing and early adoption of new global products. The company’s more than 1,000 employees serve thousands of medical aesthetics hospitals and clinics across China.
Core Business Showcase: Frontier New Products Make Their CIIE Debut
Relevant market research indicates that demand among Chinese medical aesthetics consumers is robust, with growth rates expected to remain above 10% in the near future, outpacing the global average. The continuous launch of new products fosters healthy competition within the industry and provides consumers with greater choice. Meanwhile, technological innovation is driving greater transparency in industry information, while standardized procedures and regulatory compliance are bolstering market confidence.1
As one of the medical aesthetics companies with the most abundant global resources, Allergan Aesthetics is committed to exploring new possibilities in the field of medical aesthetics and developing innovative products and treatments based on cutting-edge science.
At this CIIE, Allergan Aesthetics will showcase Botox, its botulinum toxin product that has been marketed globally for over 30 years.®、Hyaluronic Acid Brand: Juvederm®Product series approved in China, including the earliest to enter the Chinese market: Jizhi®He Yazhi®Juvéderm, the first hyaluronic acid filler approved in China for indications in the cheek area (including the mid-face)®Voluma®XC, as well as Juvederm, the only hyaluronic acid product currently approved in China for lip injection®Zhiyan®。
The All-New Upgraded CoolSculpting®The non-invasive cryolipolysis device utilizes the new-generation CoolAdvantage™ Series Applicators®, reducing the treatment time per area to 35 minutes while ensuring safety and efficacy, which represents a 42% reduction compared to first-generation technology.2, and provide patients with a more comfortable experience3。
Allergan Aesthetics will also showcase two Juvederm products currently available in the Hainan Boao Lecheng International Medical Tourism Pilot Zone.®Flagship Product — Juvéderm, the First Hyaluronic Acid Product in China for Improving Chin and Jawline Facial Volume® Volux®, as well as Juvéderm, which fills the domestic market gap for cross-linked hyaluronic acid products that improve fine lines on the face and neck while simultaneously enhancing skin texture®Volite™. Allergan Aesthetics is among the first multinational corporations to participate in the Hainan Boao Lecheng Pilot Program and real-world studies, achieving tangible results. The company strives to enable consumers to access the latest global medical aesthetic products without having to leave China.
DiamondGlow, a Skincare Device Not Yet Launched in China®and functional skincare brand Skinmedica®will also be showcased at the China International Import Expo. Allergan Aesthetics is advancing the launch of these new products in China to meet the needs of medical aesthetics consumers as early as possible.
Strategic Cooperation Signing to Boost Industry Specialization and Standardization
In addition to showcasing innovative products, Allergan Aesthetics will sign strategic cooperation agreements with institutions such as the Chinese Association of Plastics and Aesthetics, the China Non-public Medical Institutions Association, Sinopharm Holding’s Centralized Procurement Center, and the Zhang Disheng Foundation at the 5th China International Import Expo, with initiatives covering the advancement of professional education for physicians.
Allergan Aesthetics has long advocated for the establishment of a medical aesthetics professional education system that aligns with market scale, consumer demand, and industry development through sustained investment in human resources, capital, and technology. The company’s dedicated medical education division, Allergan Institute, boasts a professional education team of over 100 specialists in China. With support from the local governments of Chengdu and Shanghai, it has established two innovation centers based on non-commercial medical aesthetic clinics, offering globally leading professional medical education and hands-on training courses. During this China International Import Expo (CIIE), these two innovation centers will connect live to the exhibition venue to remotely showcase their educational achievements.
At the China International Import Expo, Allergan Aesthetics will continue to play a pivotal role in promoting industry standardization. In partnership with the Chinese Society of Plastic and Aesthetic Surgery (CSPAS), it will jointly compile the “Report on the Development of China’s Medical Aesthetics Industry,” advancing the concept of the “Three Legitimates”—namely, legitimate hospitals, legitimate physicians, and legitimate products—and promoting the “Scan-to-Verify” initiative to ensure consumers use authentic products.
Allergan Aesthetics will also share its corporate innovation culture and convey its talent development philosophy at the China International Import Expo.
Qiu Hanhuastated: “The 5th China International Import Expo (CIIE) serves not only as a platform to showcase Allergan Aesthetics’ comprehensive strengths in products, technologies, and services, but also as a stage where core forces of China’s medical aesthetics industry gather to demonstrate confidence in the future. We hope that this CIIE will help unite stakeholders across the industry and create opportunities for the sustainable, high-quality development of China’s medical aesthetics sector.”
Allergan Aesthetics, an AbbVie company, is dedicated to the research and development, production, and sales of a portfolio of leading aesthetic brands and products, spanning facial aesthetics, body contouring, plastic surgery, and skincare.
Allergan Aesthetics has an independent R&D department dedicated to advancing breakthrough innovations in the field of aesthetics, providing comprehensive and scientifically backed aesthetic products.
1. Allergan Aesthetics and Deloitte Consulting Jointly Released the "2022 Annual Insights Report on China's Medical Aesthetics Industry"
2. Treatment times vary for different applicators in the CoolAdvantage™ series
3. Suzanne L. Kilmer,Prototype CoolCup Cryolipolysis Applicator With Over 40% Reduced Treatment Time Demonstrates Equivalent Safety
and Efficacy With Greater Patient Preference, Lasers in Surgery and Medicine Published by Wiley Periodicals, Inc.